GSK is accused of making a drug for… heartburn Zantac may have increased the risk of cancer. The British pharmaceutical company announced that it had reached agreements with 10 law firms representing around 80,000 people. people. 93 percent of the cases were settled with settlements where the company will pay USD 2.2 billion. compensation In a statement to investors, the company said that while there is “no consistent or credible evidence” that the drug increases the risk of cancer, the settlements “remove significant financial uncertainty,” the BBC reports.
Zantac was the best selling drug in the world. In 2020, it was withdrawn from the US market
Zantac was approved for sale in the United States in 1983. Within five years, it was the best-selling drug in the world, with annual sales exceeding $1 billion. In 2020, the US Food and Drug Administration (FDA) asked manufacturers to withdraw the drug from the market, Bloomberg reports.
There were fears that its main ingredient, ranitidine, could transform under the influence of heat into a substance that increases the risk of cancer, NDMA. In addition to GSK, the drug was sold by other major pharmaceutical companies: Pfizer, Sanofi and Boehringer Ingelheim. Another version of the drug is still on the market, Zantac 360, which does not contain ranitidine.
2024-10-13 16:05:00
#pharmaceutical #company #pay #billions #Heartburn #medication #increased #risk #cancer
